News

Federal Funds Launch First Alzheimer's Prevention Study


 

FROM A RESEARCH SUMMIT SPONSORED BY THE NATIONAL INSTITUTE ON AGING

Genentech is sponsoring the crenezumab study. Dr. Reiman had no personal financial disclosures. Dr. Craft had no financial disclosures.

*Correction 5/20/12: An earlier version of this story misidentified the investigational immunotherapy drug that was associated with adverse events in Alzheimer’s disease patients.

Pages

Recommended Reading

Delirium Due to Medical Cause Often Misdiagnosed as Psychiatric Disorder
MDedge Psychiatry
Single Question Flags Depression in Chronic Pain
MDedge Psychiatry
Diabetes Managed More Tightly in Demented Patients
MDedge Psychiatry
Asymptomatic Neurocognitive Impairment Quantified in HIV-Positive Patients
MDedge Psychiatry
Ask Alzheimer's Patient Caregiver: Patch or Pill Therapy?
MDedge Psychiatry
Neuropsychological Impairment Detected Early in Course of HIV
MDedge Psychiatry
Amyloid Imaging Agent May Aid Alzheimer's Diagnosis
MDedge Psychiatry
Azotemia, Anemia Predict Medical Deterioration in Dementia Inpatients
MDedge Psychiatry
Autopsy, Biopsy Data Support Amyloid Imaging Agents
MDedge Psychiatry
Amyloid-Beta-Associated Cognitive Decline Only Occurs at High P-Tau Levels
MDedge Psychiatry

Related Articles